🇫🇷 IPN.PA — Ipsen S.A.

Salud Mantener
← Volver

Precio actual

153,20 EUR

Máx. histórico

172,90

181 días

Caída desde máximo

-11,39%

Rango 52 semanas

115,60 – 174,00

Variación hoy

-1,42%

Cierre anterior

155,40

Rango de hoy

152,70 – 157,00

Volumen hoy

131.211

Peor caída histórica

-75,62%

30/08/2018 → 18/03/2020

Recuperado en 2157 días

Volatilidad anualizada ⓘ

30,51%

Información
Nombre completo
Ipsen S.A.
Divisa
EUR
Mercado
Paris
Sector
Salud
Industria
Drug Manufacturers - Specialty & Generic
Empleados
5.535
PER ⓘ
24,79 (puede no estar actualizado)
Dividend yield
1,03% (puede no estar actualizado)
Precio objetivo analistas
161,92 EUR (puede no estar actualizado)
Primera cotización
07/12/2005
Precio actualizado
hace 1 día
Sobre la empresa

Ipsen S.A., a biopharmaceutical company, develops and commercializes medicines in the areas of oncology, rare disease, and neuroscience in North America, Europe, and internationally. It engages in the development of Somatuline for neuroendocrine tumors and acromegaly indications; and Dysport for motor muscular disorders and medical aesthetics indications; and Decapeptyl for advanced metastatic prostate cancer, uterine fibroids, central precocious puberty, endometriosis, female infertility, and early-stage breast cancer in combination with hormone therapy. The company also develops Cabometyx for renal cell carcinoma, second line hepatocellular carcinoma, differentiated thyroid cancer, and neuroendocrine tumors; Onivyde for second-line metastatic pancreatic cancer; and Bylvay for the treatment of progressive familial intrahepatic cholestasis and cholestatic pruritus in patients with both PFIC and Alagille syndrome. In addition, it is involved in the development of Iqirvo for the second line treatment for primary biliary cholangitis; Sohonos for the treatment to reduce new, abnormal bone formation in soft and connective tissues, in people living with ultra-rare bone disease, and fibrodysplasia ossificans progressiva; and IPN60340 in Phase I/II clinical trial for first line acute myeloid leukemia indications. Further, the company develops Tazverik + rituximab and lenalidomide in Phase III clinical trials for second line follicular lymphoma indications; Tovorafenib in Phase III clinical trials for first line pediatric low-grade gliomas indications; and IPN01194, IPN01195, IPN60300, and IPN01203 in Phase I for solid tumors indications; and IPN10200 in Phase II clinical trials for aesthetic and therapeutic indications. Ipsen S.A. was founded in 1929 and is headquartered in Paris, France.

Dividendos repartidos Total últimos 12 meses: 1,6000 EUR · Yield: 1,04%
Fecha de pago Importe por participación
03/06/2026 1,6000 EUR
04/06/2025 1,4000 EUR
30/05/2024 1,2000 EUR
02/06/2023 1,2000 EUR
31/05/2022 1,2000 EUR
31/05/2021 1,0000 EUR
03/06/2020 1,0000 EUR
31/05/2019 1,0000 EUR
04/06/2018 1,0000 EUR
09/06/2017 0,8500 EUR
02/06/2016 0,8500 EUR
29/05/2015 0,8500 EUR
09/06/2014 0,8000 EUR
05/06/2013 0,8000 EUR
06/06/2012 0,8000 EUR
Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
22/03/2021 68,20 69,15 67,50 69,15 +1,69% 2,42% 132.505
19/03/2021 66,75 68,35 66,75 68,00 +1,57% 2,40% 215.107
18/03/2021 66,90 68,45 66,80 66,95 +0,15% 2,47% 89.940
17/03/2021 67,60 67,80 66,20 66,85 -1,04% 2,37% 151.927
16/03/2021 67,20 68,20 67,10 67,55 +0,67% 1,64% 130.323
15/03/2021 66,75 67,30 66,50 67,10 +0,90% 1,20% 87.399
12/03/2021 67,60 68,45 66,50 66,50 -1,92% 2,88% 120.416
11/03/2021 68,90 69,60 67,45 67,80 -1,31% 3,12% 151.249
10/03/2021 66,85 68,85 66,55 68,70 +2,77% 3,44% 249.501
09/03/2021 66,35 68,15 65,90 66,85 +0,75% 3,39% 179.246
08/03/2021 70,15 70,55 65,90 66,35 -5,21% 6,63% 322.812
05/03/2021 69,95 71,45 69,60 70,00 -0,99% 2,64% 83.695
04/03/2021 70,40 71,00 69,75 70,70 +0,35% 1,78% 103.518
03/03/2021 70,30 70,90 69,75 70,45 +0,36% 1,64% 107.734
02/03/2021 70,65 70,90 69,95 70,20 -0,78% 1,34% 119.274
01/03/2021 71,10 72,70 70,60 70,75 +0,14% 2,95% 112.251
26/02/2021 70,65 71,85 69,70 70,65 -0,63% 3,04% 132.557
25/02/2021 71,65 71,95 70,80 71,10 -0,56% 1,61% 69.420
24/02/2021 69,70 71,85 69,70 71,50 +2,29% 3,08% 91.425
23/02/2021 70,70 71,10 69,80 69,90 -0,71% 1,84% 76.986
22/02/2021 70,10 71,10 69,30 70,40 +0,21% 2,57% 78.676
19/02/2021 70,80 71,85 70,05 70,25 -0,92% 2,54% 90.303
18/02/2021 71,00 71,45 70,05 70,90 -0,07% 1,97% 128.166
17/02/2021 71,00 71,45 69,55 70,95 -0,21% 2,68% 130.492
16/02/2021 72,50 72,50 70,75 71,10 -1,93% 2,41% 123.869
15/02/2021 74,90 75,35 72,45 72,50 -2,55% 3,87% 132.869
12/02/2021 74,70 76,00 73,40 74,40 -1,52% 3,48% 144.863
11/02/2021 75,90 78,10 74,75 75,55 -0,07% 4,41% 153.637
10/02/2021 75,50 76,05 74,30 75,60 +0,53% 2,32% 121.163
09/02/2021 74,50 75,20 73,35 75,20 +1,76% 2,48% 119.811